Amicus Therapeutics, Inc. (FOLD) Stock Price Down 5.8%
Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares fell 5.8% during mid-day trading on Friday . The company traded as low as $14.92 and last traded at $15.06. 3,920,610 shares changed hands during trading, a decline of 5% from the average session volume of 4,132,900 shares. The stock had previously closed at $15.98.
A number of research firms have issued reports on FOLD. BidaskClub lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Chardan Capital boosted their target price on shares of Amicus Therapeutics from $12.50 to $17.50 and gave the company a “buy” rating in a research note on Thursday, August 10th. Zacks Investment Research raised shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 19th. J P Morgan Chase & Co reissued an “overweight” rating on shares of Amicus Therapeutics in a research note on Wednesday. Finally, Robert W. Baird reissued an “outperform” rating and set a $18.00 target price (up from $16.00) on shares of Amicus Therapeutics in a research note on Wednesday. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Amicus Therapeutics presently has a consensus rating of “Buy” and an average target price of $18.07.
The company’s market capitalization is $2.48 billion. The firm has a 50 day moving average price of $14.11 and a 200 day moving average price of $10.59.
Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.03. The firm had revenue of $7.16 million during the quarter, compared to analysts’ expectations of $6.96 million. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. During the same quarter last year, the company posted ($0.40) EPS. On average, equities research analysts anticipate that Amicus Therapeutics, Inc. will post ($1.32) earnings per share for the current year.
In related news, major shareholder Life Sciences Maste Perceptive acquired 1,500,000 shares of the stock in a transaction on Thursday, July 13th. The stock was purchased at an average price of $12.25 per share, for a total transaction of $18,375,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 3.40% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of FOLD. Janus Henderson Group PLC acquired a new stake in Amicus Therapeutics in the 2nd quarter valued at about $70,762,000. Wellington Management Group LLP increased its position in Amicus Therapeutics by 358.4% in the 1st quarter. Wellington Management Group LLP now owns 5,341,132 shares of the biopharmaceutical company’s stock valued at $38,083,000 after acquiring an additional 4,175,995 shares in the last quarter. Morgan Stanley increased its position in Amicus Therapeutics by 99.4% in the 1st quarter. Morgan Stanley now owns 6,128,481 shares of the biopharmaceutical company’s stock valued at $43,696,000 after acquiring an additional 3,055,039 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in Amicus Therapeutics in the 1st quarter valued at about $21,394,000. Finally, Farallon Capital Management LLC acquired a new stake in Amicus Therapeutics in the 2nd quarter valued at about $30,210,000.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Stock Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related stocks with our FREE daily email newsletter.